$54.80
1.92[3.63%]
At close: Apr 26
$54.80
0[0.00%]
After Hours: 4:16PM EDT
Praxis Precision Medicine
(NASDAQ:PRAX)Latest News for Praxis Precision Medicine Stock (NASDAQ:PRAX)
Praxis Precision Medicine Stock (NASDAQ: PRAX)
Categories: All
Friday, April 26, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
- Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 26, 2024, 1:45PM
- Jefferies Maintains Buy on Praxis Precision Medicine, Raises Price Target to $128Benzinga Newsdesk - Mar 26, 2024, 1:32PM
- Why Praxis Precision Medicines Stock Is Trading Higher TuesdayVandana Singh - Mar 26, 2024, 12:54PM
- HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price TargetBenzinga Newsdesk - Mar 26, 2024, 12:22PM
- Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Mar 26, 2024, 10:36AM
- Praxis Precision Medicines shares are trading higher after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR.Benzinga Newsdesk - Mar 26, 2024, 9:09AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 26, 2024, 9:05AM
- Praxis Precision Medicines Reports Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated PatientsBenzinga Newsdesk - Mar 26, 2024, 6:32AM
Wednesday, March 06, 2024
Tuesday, March 05, 2024
- Recap: Praxis Precision Medicine Q4 EarningsBenzinga Insights - Mar 5, 2024, 4:55PM
- Praxis Precision Medicines Files For Mixed Shelf Offering Of Up To $750MBenzinga Newsdesk - Mar 5, 2024, 9:14AM
- Praxis Precision Medicine Q4 EPS $(2.97) Beats $(3.13) Estimate, Sales $515.00K Beat $50.00K EstimateBenzinga Newsdesk - Mar 5, 2024, 7:06AM
Thursday, January 25, 2024
Friday, January 12, 2024
Thursday, January 11, 2024
- Praxis Precision Medicines Prices Its Underwritten Public Offering Of 3.17M Shares At $35.50/Share And, In Lieu Of Shares Of Common Stock, Pre-funded Warrants To Purchase Up To 1.06M Shares At $35.4999/Pre-funded Warrant, For Gross Proceeds Of ~$150MBenzinga Newsdesk - Jan 11, 2024, 7:34AM
- On January 10, 2024, Praxis Precision Medicines Delivered Written Notice To Jefferies To Terminate Sales Agreement, Under Which Company Could Offer, Sell Shares Of Common Stock With Offering Price Of Up To $75MCharles Gross - Jan 11, 2024, 6:06AM
Wednesday, January 10, 2024
Monday, January 08, 2024
- Praxis Precision Medicines shares are trading higher after the company provided an update on its portfolio and planned key milestones in 2024.Benzinga Newsdesk - Jan 8, 2024, 1:58PM
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Jan 8, 2024, 1:36PM
- Praxis Precision Medicines Provides Update On Advancing Clinical Stage Portfolio; Recently Announced Licensing Partnership With Tenacia Biotechnology To Develop And Commercialize Ulixacaltamide In Greater China With Total Consideration Over $275MBenzinga Newsdesk - Jan 8, 2024, 8:25AM
Tuesday, December 05, 2023
Monday, December 04, 2023
Wednesday, November 29, 2023
- Praxis Precision Medicines Shares Resume TradeBenzinga Newsdesk - Nov 29, 2023, 9:00AM
- Praxis Precision Medicines Shares To Resume Trade At 9:00 a.m. ETBenzinga Newsdesk - Nov 29, 2023, 8:27AM
- Reported November 28, Praxis Precision Medicines To Showcase Largest Pipeline Of Precision Epilepsy Programs And Breadth Of Commitment To Epilepsy Treatments At Upcoming MeetingsBenzinga Newsdesk - Nov 29, 2023, 8:26AM
Wednesday, November 15, 2023
Tuesday, November 07, 2023
Tuesday, October 03, 2023
Monday, October 02, 2023
Tuesday, September 19, 2023
Wednesday, August 23, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
Monday, August 07, 2023
- FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst SaysVandana Singh - Aug 7, 2023, 12:06PM
- Praxis Precision Medicines Says Analysis Of EEG Activity For Subjects In The Recent Phase 1 Study Demonstrated Pharmacodynamic Activity Across All Dose Levels Who Received PRAX-628 At First Administration As Compared With Subjects Who Received PlaceboBenzinga Newsdesk - Aug 7, 2023, 7:20AM